Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy.

Author: , BrigellMitchell, FosterC Stephen, GrosskreutzCynthia L, LetkoErik, PleyerUwe, YehSteven

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study compared the efficacy and safety of different IV and SC doses of secukinumab in patients with noninfectious uveitis.
Paper Details　
Original Abstract of the Article :
Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibited promising activity in a proof-of-concept study when administered in intravenous (IV) doses to patients with active, chronic, noninfectious uveitis. This study compared the efficacy and safety of different IV and subcutane...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ophtha.2014.12.033

データ提供：米国国立医学図書館（NLM）

Secukinumab for Noninfectious Uveitis: A Promising New Treatment

The field of ophthalmology is always striving for better treatments for complex eye conditions like uveitis. This study explores the efficacy and safety of secukinumab, a novel treatment for noninfectious uveitis, a condition that can be as challenging to treat as navigating a winding path through a sandstorm.

A New Pathway to Vision Preservation

The researchers conducted a comprehensive study comparing different doses of secukinumab, both intravenously and subcutaneously, in patients with noninfectious uveitis. The results suggest that secukinumab could be an effective and safe treatment option, offering a refreshing spring in the desert of uveitis treatments.

Hope for Better Vision

The findings suggest that secukinumab could offer a new pathway to preserving vision for individuals struggling with noninfectious uveitis. Like finding a hidden oasis in the vast desert, this research offers hope for better treatment options for this challenging condition.

Dr. Camel's Conclusion

This study is a beacon of light in the search for effective treatments for noninfectious uveitis. Secukinumab holds promise for improving the lives of patients with this condition, offering a chance to navigate the challenges of eye health with greater clarity.

Date :
  1. Date Completed 2015-07-16
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

25638011

DOI: Digital Object Identifier

10.1016/j.ophtha.2014.12.033

Related Literature

Article Analysis
・Effects of secukinumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.